The Natural Course of Non-Alcoholic Fatty Liver Disease

Luis Calzadilla Bertot, Leon Anton Adams, Luis Calzadilla Bertot, Leon Anton Adams

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world, paralleling the epidemic of obesity and Type 2 diabetes mellitus (T2DM). NAFLD exhibits a histological spectrum, ranging from "bland steatosis" to the more aggressive necro-inflammatory form, non-alcoholic steatohepatitis (NASH) which may accumulate fibrosis to result in cirrhosis. Emerging data suggests fibrosis, rather than NASH per se, to be the most important histological predictor of liver and non-liver related death. Nevertheless, only a small proportion of individuals develop cirrhosis, however the large proportion of the population affected by NAFLD has led to predictions that NAFLD will become a leading cause of end stage liver disease, hepatocellular carcinoma (HCC), and indication for liver transplantation. HCC may arise in non-cirrhotic liver in the setting of NAFLD and is associated with the presence of the metabolic syndrome (MetS) and male gender. The MetS and its components also play a key role in the histological progression of NAFLD, however other genetic and environmental factors may also influence the natural history. The importance of NAFLD in terms of overall survival extends beyond the liver where cardiovascular disease and malignancy represents additional important causes of death.

Keywords: cirrhosis; fibrosis; hepatocellular carcinoma; non-alcoholic steatohepatitis; non-cirrhotic; nonalcoholic fatty liver.

Figures

Figure 1
Figure 1
Progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) with or without fibrosis, cirrhosis, and hepatocellular carcinoma. Data adapted form [7,8,9] and [24].

References

    1. NCD-RisC Trends in adult body mass index in 200 countries from 1975 to 2014. Lancet. 2016;387:1377–1396.
    1. Ray K. NAFLD–The next global epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013;10:621. doi: 10.1038/nrgastro.2013.197.
    1. Powell E.E., Cooksley W.G.E., Hanson R., Searle J., Halliday J.W., Powell W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80. doi: 10.1002/hep.1840110114.
    1. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., Driscoll C.J. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–669. doi: 10.1002/hep.510290347.
    1. Poonawala A., Nair S.P., Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology. 2000;32:689–692. doi: 10.1053/jhep.2000.17894.
    1. Teli M.R., James O.F., Burt A.D., Bennett M.K., Day C.P. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology. 1995;22:1714–1719. doi: 10.1002/hep.1840220616.
    1. Wong V.W.-S., Wong G.L.-H., Choi P.C.-L., Chan A.W.-H., Li M.K.-P., Chan H.-Y., Chim A.M., Yu J., Sung J.J., Chan H.L. Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974. doi: 10.1136/gut.2009.205088.
    1. Pais R., Charlotte F., Fedchuk L., Bedossa P., Lebray P., Poynard T., Ratziu V., LIDO Study Group A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 2013;59:550–556. doi: 10.1016/j.jhep.2013.04.027.
    1. McPherson S., Hardy T., Henderson E., Burt A.D., Day C.P., Anstee Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J. Hepatol. 2015;62:1148–1155. doi: 10.1016/j.jhep.2014.11.034.
    1. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., Enders F., Saksena S., Burt A.D., Bida J.P., et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854. doi: 10.1002/hep.21496.
    1. Ekstedt M., Franzén L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873. doi: 10.1002/hep.21327.
    1. Adams L.A., Sanderson S., Lindor K.D., Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005;42:132–138. doi: 10.1016/j.jhep.2004.09.012.
    1. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362. doi: 10.1002/hep.510300604.
    1. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterol.-Orlando. 1994;107:1103–1109.
    1. Evans C., Oien K., MacSween R., Mills P. Non-alcoholic steatohepatitis: A common cause of progressive chronic liver injury? J. Clin. Pathol. 2002;55:689–692. doi: 10.1136/jcp.55.9.689.
    1. Fassio E., Álvarez E., Domínguez N., Landeira G., Longo C. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820–826. doi: 10.1002/hep.1840400411.
    1. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: A clinical histopathological study. Am. J. Gastroenterol. 2003;98:2042–2047. doi: 10.1111/j.1572-0241.2003.07659.x.
    1. Hui A., Wong V.S., Chan H.Y., Liew C.T., Chan J.Y., Chan F.L., Sung J.Y. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment. Pharmacol. Ther. 2005;21:407–413. doi: 10.1111/j.1365-2036.2005.02334.x.
    1. Lee R.G. Nonalcoholic steatohepatitis: A study of 49 patients. Hum. Pathol. 1989;20:594–598. doi: 10.1016/0046-8177(89)90249-9.
    1. Ratziu V., Giral P., Charlotte F., Bruckert E., Thibault V., Theodorou I., Khalil L., Turpin G., Opolon P., Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–1123. doi: 10.1016/S0016-5085(00)70364-7.
    1. Duan X.F., Tang P., Li Q., Yu Z.T. Obesity, adipokines and hepatocellular carcinoma. Int. J. Cancer. 2013;133:1776–1783. doi: 10.1002/ijc.28105.
    1. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., Thaiss C.A., Kau A.L., Eisenbarth S.C., Jurczak M.J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–185. doi: 10.1038/nature10809.
    1. Oliveira C.P., Stefano J.T. Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): A mini review. Clin. Res. Hepatol. Gastroenterol. 2015;39:S35–S40. doi: 10.1016/j.clinre.2015.05.014.
    1. Singh S., Allen A.M., Wang Z., Prokop L.J., Murad M.H., Loomba R. Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 2015;13:643–654. doi: 10.1016/j.cgh.2014.04.014.
    1. McPherson S., Stewart S.F., Henderson E., Burt A.D., Day C.P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–1269. doi: 10.1136/gut.2010.216077.
    1. Hossain N., Afendy A., Stepanova M., Nader F., Srishord M., Rafiq N., Goodman Z., Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009;7:1224–1229. doi: 10.1016/j.cgh.2009.06.007.
    1. Yang J.D., Abdelmalek M.F., Pang H., Guy C.D., Smith A.D., Diehl A.M., Suzuki A. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406–1414. doi: 10.1002/hep.26761.
    1. Klair J.S., Yang J.D., Abdelmalek M.F., Guy C.D., Gill R.M., Yates K., Unalp-Adrida A., Lavine J., Clark J., Diehl A.M., et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016 doi: 10.1002/hep.28514.
    1. Lomonaco R., Ortiz-Lopez C., Orsak B., Finch J., Webb A., Bril F., Louden C., Tio F., Cusi K. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54:837–845. doi: 10.1002/hep.24483.
    1. Bambha K., Belt P., Abraham M., Wilson L.A., Pabst M., Ferrell L., Unalp-Arida A., Bass N. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769–780. doi: 10.1002/hep.24726.
    1. Mohanty S.R., Troy T.N., Huo D., O’Brien B.L., Jensen D.M., Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J. Hepatol. 2009;50:797–804. doi: 10.1016/j.jhep.2008.11.017.
    1. Solga S.F., Clark J.M., Alkhuraishi A.R., Torbenson M., Tabesh A., Schweitzer M., Diehl A.M., Magnuson T.H. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg. Obes. Relat. Dis. 2005;1:6–11. doi: 10.1016/j.soard.2004.12.006.
    1. Kallwitz E.R., Guzman G., TenCate V., Vitello J., Layden-Almer J., Berkes J., Patel R., Layden T.J., Cotler S.J. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am. J. Gastroenterol. 2009;104:64–69. doi: 10.1038/ajg.2008.12.
    1. Liu Y.L., Reeves H.L., Burt A.D., Tiniakos D., McPherson S., Leathart J.B., Allison M.E., Alexander G.J., Piguet A.C., Anty R., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 2014;5:4309. doi: 10.1038/ncomms5309.
    1. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., Boerwinkle E., Cohen J.C., Hobbs H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008;40:1461–1465. doi: 10.1038/ng.257.
    1. Valenti L., Al-Serri A., Daly A.K., Galmozzi E., Rametta R., Dongiovanni P., Nobili V., Mozzi E., Roviaro G., Vanni E., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–1217. doi: 10.1002/hep.23622.
    1. Eslam M., Hashem A.M., Romero-Gomez M., Berg T., Dore G.J., Mangia A., Chan H.L., Irving W.L., Sheridan D., Abate M.L., et al. FibroGENE: A gene-based model for staging liver fibrosis. J. Hepatol. 2016;64:390–398. doi: 10.1016/j.jhep.2015.11.008.
    1. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–910. doi: 10.1016/S2213-8587(14)70032-4.
    1. Neuschwander-Tetri B.A., Clark J.M., Bass N.M., van Natta M.L., Unalp-Arida A., Tonascia J., Zein C.O., Brunt E.M., Kleiner D.E., McCullough A.J., et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913–924. doi: 10.1002/hep.23784.
    1. Tarantino G., Conca P., Riccio A., Tarantino M., di Minno M.N., Chianese D., Pasanisi F., Contaldo F., Scopacasa F., Capone D. Enhanced serum concentrations of transforming growth factor-β1 in simple fatty liver: Is it really benign? J. Transl. Med. 2008;6:72. doi: 10.1186/1479-5876-6-72.
    1. Adams L.A., Lymp J.F., Sauver J.S., Sanderson S.O., Lindor K.D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129:113–121. doi: 10.1053/j.gastro.2005.04.014.
    1. Williams C.D., Stengel J., Asike M.I., Torres D.M., Shaw J., Contreras M., Landt C.L., Harrison S.A. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 2011;140:124–131. doi: 10.1053/j.gastro.2010.09.038.
    1. Dam-Larsen S., Becker U., Franzmann M.B., Larsen K., Christoffersen P., Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand. J. Gastroenterol. 2009;44:1236–1243. doi: 10.1080/00365520903171284.
    1. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419. doi: 10.1016/S0016-5085(99)70506-8.
    1. El-serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–468. doi: 10.1053/j.gastro.2003.10.065.
    1. Loomba R., Abraham M., Unalp A., Wilson L., Lavine J., Doo E., Bass N.M. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–951. doi: 10.1002/hep.25772.
    1. Hui J.M., Kench J.G., Chitturi S., Sud A., Farrell G.C., Byth K., Hall P., Khan M., George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420–427. doi: 10.1053/jhep.2003.50320.
    1. Sanyal A.J., Banas C., Sargeant C., Luketic V.A., Sterling R.K., Stravitz R.T., Shiffman M.L., Heuman D., Coterrell A., Fisher R.A., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–689. doi: 10.1002/hep.21103.
    1. Singal A.K., Guturu P., Hmoud B., Kuo Y.-F., Salameh H., Wiesner R.H. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755–760. doi: 10.1097/TP.0b013e31827afb3a.
    1. Agopian V.G., Kaldas F.M., Hong J.C., Whittaker M., Holt C., Rana A., Zarrinpar A., Petrowsky H., Farmer D., Yersiz H., et al. Liver transplantation for nonalcoholic steatohepatitis: The new epidemic. Ann. Surg. 2012;256:624–633. doi: 10.1097/SLA.0b013e31826b4b7e.
    1. Charlton M.R., Burns J.M., Pedersen R.A., Watt K.D., Heimbach J.K., Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253. doi: 10.1053/j.gastro.2011.06.061.
    1. Wong R.J., Aguilar M., Cheung R., Perumpail R.B., Harrison S.A., Younossi Z.M., Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555. doi: 10.1053/j.gastro.2014.11.039.
    1. Caldwell S.H., Crespo D.M. The spectrum expanded: Cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J. Hepatol. 2004;40:578–584. doi: 10.1016/j.jhep.2004.02.013.
    1. Long M.T., Wang N., Larson M.G., Mitchell G.F., Palmisano J., Vasan R.S., Hoffmann U., Speliotes E.K., Vita J.A., Benjamin E.J., et al. Nonalcoholic fatty liver disease and vascular function: Cross-sectional analysis in the Framingham heart study. Arterioscler. Thromb. Vasc. Biol. 2015;35:1284–1291. doi: 10.1161/ATVBAHA.114.305200.
    1. Huang R.C., Beilin L.J., Ayonrinde O., Mori T.A., Olynyk J.K., Burrows S., Hands B., Adams L.A. Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents. Hepatology. 2013;58:1306–1314. doi: 10.1002/hep.26495.
    1. VanWagner L.B., Wilcox J.E., Colangelo L.A., Lloyd-Jones D.M., Carr J.J., Lima J.A., Lewis C.E., Rinella M.E., Shah S.J. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015;62:773–783. doi: 10.1002/hep.27869.
    1. Oni E.T., Agatston A.S., Blaha M.J., Fialkow J., Cury R., Sposito A., Erbel R., Blankstein R., Feldman T., Al-Mallah M.H., et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230:258–267. doi: 10.1016/j.atherosclerosis.2013.07.052.
    1. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013;10:330–344. doi: 10.1038/nrgastro.2013.41.
    1. Vanni E., Marengo A., Mezzabotta L., Bugianesi E. Systemic complications of nonalcoholic fatty liver disease: When the liver is not an innocent bystander. Semin. Liver Dis. 2015;35:236–249. doi: 10.1055/s-0035-1562944.
    1. Kim D., Kim W.R., Kim H.J., Therneau T.M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–1365. doi: 10.1002/hep.26156.
    1. Haring R., Wallaschofski H., Nauck M., Dorr M., Baumeister S.E., Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009;50:1403–1411. doi: 10.1002/hep.23135.
    1. Ekstedt M., Hagström H., Nasr P., Fredrikson M., Stål P., Kechagias S., Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554. doi: 10.1002/hep.27368.
    1. Adams L.A., Ratziu V. Non-alcoholic fatty liver—Perhaps not so benign. J. Hepatol. 2015;62:1002–1004. doi: 10.1016/j.jhep.2015.02.005.
    1. Younossi Z.M., Stepanova M., Rafiq N., Makhlouf H., Younoszai Z., Agrawal R., Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882. doi: 10.1002/hep.24268.
    1. Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., Mills P.R., Keach J.C., Lafferty H.D., Stahler A., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397. doi: 10.1053/j.gastro.2015.04.043.
    1. Bruix J., Gores G.J., Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 2014;63:844–855. doi: 10.1136/gutjnl-2013-306627.
    1. Dyson J., Jaques B., Chattopadyhay D., Lochan R., Graham J., Das D., Aslam T., Patanwala I., Gaggar S., Cole M., et al. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. J. Hepatol. 2014;60:110–117. doi: 10.1016/j.jhep.2013.08.011.
    1. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. J. Hepatol. 2012;56:1384–1391. doi: 10.1016/j.jhep.2011.10.027.
    1. Park E.J., Lee J.H., Yu G.-Y., He G., Ali S.R., Holzer R.G., Österreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208. doi: 10.1016/j.cell.2009.12.052.
    1. Zámbó V., Simon-Szabó L., Szelényi P., Kereszturi E., Bánhegyi G., Csala M. Lipotoxicity in the liver. World J. Hepatol. 2013;5:550–557.
    1. Mittal S., Sada Y.H., El-Serag H.B., Kanwal F., Duan Z., Temple S., May S.B., Kramer J.R., Richardson P.A., Davila J.A. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin. Gastroenterol. Hepatol. 2015;13:594–601. doi: 10.1016/j.cgh.2014.08.013.
    1. Kawamura Y., Arase Y., Ikeda K., Seko Y., Imai N., Hosaka T., Kobayashi M., Saitoh S., Sezaki H., Akuta N., et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am. J. Gastroenterol. 2012;107:253–261. doi: 10.1038/ajg.2011.327.
    1. Ertle J., Dechene A., Sowa J.P., Penndorf V., Herzer K., Kaiser G., Schlaak J.F., Gerken G., Syn W.K., Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer. 2011;128:2436–2443. doi: 10.1002/ijc.25797.
    1. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 2012;10:1342–1359. doi: 10.1016/j.cgh.2012.10.001.
    1. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978. doi: 10.1002/hep.23527.
    1. Yatsuji S., Hashimoto E., Tobari M., Taniai M., Tokushige K., Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 2009;24:248–254. doi: 10.1111/j.1440-1746.2008.05640.x.
    1. Sorrentino P., D’Angelo S., Ferbo U., Micheli P., Bracigliano A., Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J. Hepatol. 2009;50:351–357. doi: 10.1016/j.jhep.2008.09.011.
    1. Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am. J. Gastroenterol. 2013;108:881–891. doi: 10.1038/ajg.2013.5.
    1. Piscaglia F., Svegliati-Baroni G., Barchetti A., Pecorelli A., Marinelli S., Tiribelli C., Bellentani S., Bolondi L., Zoli M., Malagotti D., et al. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study. Hepatology. 2015;47:e36–e37.
    1. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349–1354. doi: 10.1002/hep.1840360609.
    1. Guzman G., Brunt E.M., Petrovic L.M., Chejfec G., Layden T.J., Cotler S.J. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch. Pathol. Lab. Med. 2008;132:1761–1766.
    1. Reddy S.K., Steel J.L., Chen H.W., DeMateo D.J., Cardinal J., Behari J., Humar A., Marsh J.W., Geller D.A., Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–1819. doi: 10.1002/hep.25536.
    1. Leung C., Yeoh S.W., Patrick D., Ket S., Marion K., Gow P., Angus P.W. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J. Gastroenterol. 2015;21:1189–1196. doi: 10.3748/wjg.v21.i4.1189.
    1. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003;348:1625–1638. doi: 10.1056/NEJMoa021423.
    1. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V., Bedossa P., Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis. Hepatology. 2009;49:851–859. doi: 10.1002/hep.22734.
    1. Liu T.C., Vachharajani N., Chapman W.C., Brunt E.M. Noncirrhotic hepatocellular carcinoma: Derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod. Pathol. 2014;27:420–432. doi: 10.1038/modpathol.2013.148.
    1. Yasui K., Hashimoto E., Komorizono Y., Koike K., Arii S., Imai Y., Shima T., Kanbara Y., Saibara T., Mori T., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2011;9:428–433. doi: 10.1016/j.cgh.2011.01.023.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit